European Journal of Clinical Pharmacology

, Volume 28, Issue 6, pp 713–716 | Cite as

Double blind study of the influence of co-dergocrine on platelet parameters in healthy volunteers

  • H. Sinzinger
Short Communications


In 20 healthy volunteers double-blind randomized study was done to examine the effect of codergocrine (Hydergin) on platelet function. All the volunteers were pretreated with 3×1 placebo for 1 week, followed by the randomized study in which 10 volunteers each received drug or placebo for 6 weeks. Various platelet function parameters, such as the peripheral platelet count, plasma thromboxane B2, platelet sensitivity to the antigaggregatory prostaglandins PGI2, PGE1 and PGD2, ADP-in-duced aggregation, collagen-induced aggregation, the WU-test, the platelet proteins platelet factor 4 and β-thromboglobulin, malondialdehyde, circulating endothelial cells and the intracellular c-AMP level in platelets were examined. Treatment with co-dergocrine decreased platelet activity to a significant extent, as shown by a number of platelet function parameters, such as thromboxane B2, WU-test, β-thromboglobulin, platelet factor 4, malondialdehyde and ADP-induced aggregation. The findings suggest that co-dergocrine might be able to decrease platelet activity and improve interaction with the walls of to a blood-vessel significant degree.

Key words

co-dergocrine platelet function platelet proteins prostaglandins aggregation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Deinhardt J, Jacobi E, Poliwoda H (1977) Untersuchungen über den Einfluß von Hydergin auf das Thrombuswachstum in vivo (und die Adhäsivität menschlicher Blutplättchen). Med Welt 23: 1752–1754Google Scholar
  2. 2.
    Mills DCB, Roberts GCK (1967) Effects of adrenaline on human blood platelets. J Physiol 193: 443Google Scholar
  3. 3.
    Perez Sanchez M, Rocha Cosas E, Pico M, Cabezuelo A, Fernandez MT (1978) Ensayo clinico de los alcalosdes dihidrogenadas del carnezuelo de centeno como antiagrengantes plaquetarios en patientes con AVC isquemico. In: E. Garsi (ed) X. Congr. Nac. Geront. and Gest., Graf, Orbe, Madrid, 490–494Google Scholar
  4. 4.
    Deinhart J, Jacobi E, Poliwoda H (1972) Untersuchungen über den Einfluß von Hydergin auf das Thrombuswachstum in vivo. Med Welt 23: 1752–1754Google Scholar
  5. 5.
    Durrafourd P, Lavien H (1968) Etude thrombelastographique de l'action d'un vaso-regulateur en postopérative. Effet preventif de l'aggregation plaquettaire dans la microcirculation (effet “antisludge”). Interpretation statistique. Ann Chir 22: 819–824Google Scholar
  6. 6.
    Wu KK, Hoak JC (1974) A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1: 924Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • H. Sinzinger
    • 1
  1. 1.Atherosclerosis Research Group at the Department of Medical Physiology (ASF)University of Vienna and Atherosclerosis and Thrombosis Research Group (ATK) of the Austrian Academy of SciencesViennaAustria

Personalised recommendations